In vitro activity of commercial formulation and active principle of trypanocidal drugs against blooststreams forms of Trypanosoma brucei gambiense

African Journal of Biotechnology

Volumn 2, Issue 11, 2003, Pages 534-539

  Likeufack, Clarisse Lekane ^a   Tongue, Lisette Kohagne ^a   Truc, Philippe ^a,b  

^a Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Commercial formulations; In vitro activity; Trypanocidal drugs; Trypanosoma brucei gambiense

Indexed keywords

5 NITROFURAN; ANTITRYPANOSOMAL AGENT; EFLORNITHINE; NIFURTIMOX; PENTAMIDINE ISETHIONATE; SURAMIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; GENETIC STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; TRYPANOSOMA GAMBIENSE;

TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE;

EID: 3042634433     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Hirumi H, Hirumi K (1994). Axenic culture of african trypanosome bloodstream forms. Parasitol. Today 10: 80-84.
2. Kaminsky R, Brun R (1993). In vitro assays to determine drug sensitivities of African trypanosomes: a review. Acta Trop. 54: 279-289. [PubMed]
3. Kaminsky R, Zweygarth E (1989). Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi. Antimicrob. Agents Chemother. 33: 881-885. [PubMed]
4. Matovu E, Enyaru JCK, Legros D, Schmid C, Seeback T, Kaminsky R (2001). Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health 6: 407-411. [PubMed]
5. Ollivier G, Legros D (2001). Trypanosomiase humaine africaine: historique de la thérapeutique et de ses échecs. Trop. Med. Int. Health 6: 855-863. [PubMed]
6. World Health Organization (1998). Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee, WHO Technical Report Series 881.